Intrinsiqq
Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc. Insider Trading

GALT

Compare
Last 12 months

Insiders bought 65K and sold $2.94M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market
−$2.87M
6 buys · 14 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
2 / 4
executives and directors
Last open-market buy
Feb 2026
Feb 6, 2026

Get an email when GALT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jul 1410b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 16,250 at $5.13
    83K
    100% of stake
  • Jun 26 – 2910b5-1 plan
    Harold H. Shlevin
    Director · sold 30,000 at avg $5.03
    151K
    82% of stake
  • Jun 26 – 2910b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 52,037 at avg $5.04
    262K
    100% of stake
  • Jun 2310b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 7,557 at $3.14
    24K
    100% of stake
  • May 2610b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 568 at $3.10
    2K
    100% of stake
  • Feb 6
    Kary Eldred
    Director · bought 300 at $2.70
    $810
    0.4% of stake
  • Jan 2 – 610b5-1 plan
    Joel Lewis
    President and CEO · sold 84,000 at avg $3.83
    321K
    9.1% of stake
  • Jan 2 – 610b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 60,000 at avg $3.89
    233K
    89% of stake
  • Jan 2 – 610b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 60,000 at avg $3.88
    233K
    100% of stake
  • Dec 31, 202510b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 8,125 at $4.07
    33K
    100% of stake
  • Dec 23, 2025
    Kevin D Freeman
    Director · bought 5,500 at $3.55
    20K
    3.7% of stake
  • Dec 23, 2025
    Kevin D Freeman
    Director · bought 5,500 at $3.55
    20K
    4.2% of stake
  • Dec 23, 2025
    Kevin D Freeman
    Director · bought 5,500 at $3.55
    20K
    4.2% of stake
  • Dec 23, 2025
    Kary Eldred
    Director · bought 700 at $3.73
    3K
    1.0% of stake
  • Dec 23, 2025
    Kary Eldred
    Director · bought 700 at $3.73
    3K
    1.0% of stake
  • Dec 17, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 7,829 at $7.06
    55K
    0.9% of stake
  • Dec 17, 202510b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 19,442 at avg $7.04
    137K
    100% of stake
  • Dec 17, 202510b5-1 plan
    Harold H. Shlevin
    Director · sold 24,499 at avg $7.04
    172K
    79% of stake
  • Dec 16, 2025No plan
    James C Czirr
    Large holder · sold 30,681 at $6.66
    204K
    0.5% of stake
  • Dec 12, 2025 – Dec 15, 202510b5-1 plan
    Harold H. Shlevin
    Director · sold 28,210 at avg $6.28
    177K
    48% of stake
  • Dec 8, 2025 – Dec 9, 202510b5-1 plan
    Harold H. Shlevin
    Director · sold 175,790 at avg $6.00
    $1.06M
    94% of stake
  • Dec 2, 2025 – Dec 3, 2025No plan
    10X Capital Management, LLC
    Large holder · sold 162,069 at avg $5.68
    921K
    2.8% of stake
  • Nov 17, 2025 – Nov 18, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 22,463 at avg $6.07
    136K
    2.6% of stake
  • Nov 17, 2025 – Nov 18, 202510b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 77,920 at avg $6.14
    479K
    91% of stake
  • Nov 13, 202510b5-1 plan
    Khurram Jamil
    Chief Medical Officer · sold 121,117 at avg $5.47
    663K
    96% of stake
  • Nov 11, 2025No plan
    10X Capital Management, LLC
    Large holder · sold 40,000 at $5.25
    210K
    0.7% of stake
  • Nov 10, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 1,867 at $6.03
    11K
    0.2% of stake
  • Nov 10, 202510b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 5,291 at avg $6.03
    32K
    41% of stake
  • Nov 5, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 200 at $6.00
    1K
    <0.1% of stake
  • Nov 5, 202510b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 600 at avg $6.00
    4K
    7.3% of stake
  • Nov 3, 2025 – Nov 4, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 15,720 at avg $6.07
    95K
    1.8% of stake
  • Nov 3, 2025 – Nov 4, 202510b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 32,439 at avg $6.06
    197K
    68% of stake
  • Oct 22, 2025No plan
    10X Capital Management, LLC
    Large holder · sold 50,000 at avg $4.94
    247K
    0.8% of stake
  • Sep 12, 202510b5-1 plan
    Jack W Callicutt
    Chief Financial Officer · sold 8,706 at $6.44
    56K
    53% of stake
  • Sep 12, 202510b5-1 plan
    Joel Lewis
    President and CEO · sold 14,000 at $6.36
    89K
    1.6% of stake
  • Jul 21, 2025
    Kary Eldred
    Director · bought 1,000 at $2.93
    3K
    1.5% of stake
  • Jul 17, 2025
    Kevin D Freeman
    Director · bought 5,000 at $2.90
    15K
    3.5% of stake
  • Dec 30, 2024
    Harold H. Shlevin
    Director · bought 6,500 at $1.16
    8K
    75% of stake
  • Dec 24, 2024
    Richard A. Zordani Jr.
    Director · bought 10,000 at $0.82
    8K
    29% of stake
  • Dec 24, 2024
    Kary Eldred
    Director · bought 13,469 at $0.82
    11K
    25% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GALT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with GALT

CompareIntrinsic value
PRLDPrelude Therapeutics Incorporated
$3.23-0.77%46
BYSIBeyondSpring Inc.
$0.33-24.49%20
RNTXRein Therapeutics Inc.
$0.37+3.58%10
JAGXJaguar Health, Inc.
$0.22-31.50%40
UNCYUnicycive Therapeutics Inc.
$3.35-5.10%10
COCPCocrystal Pharma Inc.
$0.93-4.11%10
SCNXScienture Holdings Inc.
$2.28-6.45%0
ANVSAnnovis Bio, Inc.
$0.71-5.16%10

Held by ETFs

GALT is in 5 US ETFs. The largest of them, with GALT's weight in each:

Spot a number that looks wrong? Check it in GALT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing GALT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.